Related Experiment Videos
Knowledge, attitudes, and practices among users of GLP-1 receptor agonists in Saudi Arabia: a cross-sectional study
Abdullah A Alshehri1, Mohammed K Al-Osaimi2, Nawaf N Al-Saeedi2
1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Background:
The use of glucagon-like peptide-1 (GLP-1) receptor agonists has increased rapidly in Saudi Arabia for weight management and glycaemic control. However, concerns remain regarding inappropriate use, medication safety, and misconceptions surrounding these therapies. This study assessed the knowledge, attitudes, and practices (KAP) of GLP-1 receptor agonist users in Saudi Arabia and identified factors associated with these domains.
Methods:
A cross-sectional study was conducted among adult GLP-1 receptor agonist users in Saudi Arabia between December 2025 and March 2026. Eligible participants were aged ≥18 years and had used semaglutide, liraglutide, dulaglutide, or tirzepatide within the previous 12 months. Participants were recruited through purposive snowball sampling via social media platforms. Descriptive statistics and binary logistic regression were used to assess KAP levels and associated factors.
Results:
A total of 310 participants were included. The median age was 33 years (IQR: 16), and the median BMI was 33.9 kg/m2 (IQR: 7.1). Tirzepatide was the most frequently used medication (46.1%). Good practices were reported by 54.8% of participants, whereas only 25.8% demonstrated good knowledge and 33.2% reported positive attitudes. Knowledge, attitude, and practice scores were positively correlated (ρ = 0.278-0.395; all p < 0.001). Participants aged >50 years were less likely to demonstrate good knowledge (aOR = 0.14, 95% CI: 0.04-0.82) and positive attitudes (aOR = 0.29, 95% CI: 0.09-0.91). Postgraduate education was independently associated with positive attitudes (aOR = 6.51, 95% CI: 2.23-18.99) and good practices (aOR = 4.47, 95% CI: 1.37-14.60), while female sex was associated with good practices (aOR = 2.06, 95% CI: 1.28-3.33).
Conclusion:
GLP-1 receptor agonist users demonstrated generally favourable medication-use practices but suboptimal knowledge and attitudes. Higher knowledge was associated with more positive attitudes and better practices, highlighting the importance of patient education and healthcare professional counselling to support safe and informed use.
Related Concept Videos
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Bioavailability Study Design: Healthy Subjects Versus Patients
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Surveys
Drug Regulation